Prostate Accurately Targeted Radiotherapy Investigation of Overall Treatment Time

Randomized Phase II Study of 2 Hypofractionated Radiotherapy Schedules for Low- and Intermediate-Risk Prostate Cancer

The purpose of this study is to compare the toxicity of two new radiation schedules for the treatment of prostate cancer. Patients will be randomized to receive 5 treatments delivered every other day over 11 days, or once per week over 29 days. Both of these schedules are shorter than the standard treatment which is usually 39 treatments over 8 weeks.

Inclusion Criteria:

• Low or intermediate risk prostate cancer patients as defined by:

  • Clinical stage T1-2b, Gleason Score <=7, and PSA <=20 ng/mL

• Age >= 18 years

Exclusion Criteria:

• Androgen deprivation therapy (LHRH-agonists or antiandrogens) >6 months
• Prior pelvic radiotherapy
• Anticoagulation medication (if unsafe to discontinue for gold seed insertion)
• Diagnosis of bleeding diathesis
• Large prostate (>90cm3) on imaging
• Immunosuppressive medications
• Inflammatory bowel disease